Manufacturing

Jennifer Markarian is manufacturing editor of BioPharm International.

Articles

Homology Medicines discusses how the clinical-stage biopharmaceutical company met its need for supply of adeno-associated virus vectors.

Finding Success in AAV Manufacturing

The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.

Celonic to Establish New Cell and Gene Therapy Production Site in Switzerland

The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.

VIVEbiotech to Expand Facilities for Lentiviral-Vector Manufacturing

The new facility is part of Bristol Myers Squibb’s investment into the clinical and commercial manufacturing of cell therapies for patients with aggressive hematological cancers.

Bristol Myers Squibb to Open New Cell Therapy Facility in Massachusetts

Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.

Catalent to Acquire Delphi Genetics to Expand Plasmid DNA Capabilities 

The company has completed the expansion of its laboratory facilities to accommodate the development of APIs. 

Regis Technologies Completes Expansion of its Illinois Lab Facilities 

The new business services site will house the company’s North American human resource operations, along with certain finance and information technology teams.

Gilead to Open New Location in North Carolina

The company recently installed a fully validated visual inspection system that uses artificial intelligence in an automated inspection machine.

Syntegon Validates First AI-Equipped Visual Inspection System in Production Line

WuXi STA will acquire the site’s operations and assets, including the plant, equipment, and workforce.

WuXi STA to Purchase Bristol Myers Squibb’s Switzerland Manufacturing Facility

The site, which is set to be operational in three years, will feature disposable technology and advanced technology filling lines to produce 90 million vials and 50 million pre-filled syringes a year. 

Facility Design and Engineering